首页 | 本学科首页   官方微博 | 高级检索  
     

泮托拉唑钠在健康人体内的相对生物利用度及生物等效性研究
引用本文:隋淼,王晓波,袭荣刚,孙佳丹. 泮托拉唑钠在健康人体内的相对生物利用度及生物等效性研究[J]. 中国医药导报, 2013, 10(9): 9-11,14
作者姓名:隋淼  王晓波  袭荣刚  孙佳丹
作者单位:隋淼 (解放军第二一○医院国家药物临床试验机构,辽宁大连,116021); 王晓波 (解放军第二一○医院国家药物临床试验机构,辽宁大连,116021); 袭荣刚 (解放军第二一○医院国家药物临床试验机构,辽宁大连,116021);孙佳丹 (大连医科大学,辽宁大连,116015);
摘    要:目的建立测定血浆中泮托拉唑的高效液相色谱内标法并研究泮托拉唑钠肠溶片的相对生物利用度及生物等效性。方法20名健康男性试验者随机分为两组,分别单剂量口服泮托拉唑钠肠溶片试验制剂或参比制剂40mg,于服药前(0h)和服药后0.75、1.0、1.5、2.0、2.5、3.0、3.5、4.0、5.0、6.0、8.0、10.0、12.0h抽取静脉血。7d清洗期后再交叉给药。采用高效液相色谱法测定血浆中泮托拉唑的浓度。通过WinNonlin5.2.1数据统计软件计算主要药动学参数,评价两制剂的生物等效性。结果受试制剂与参比制剂血浆中泮托拉唑片的t1/2:(1.83±0.56)h、tmax:(2.80±0.62)h、Cmax:(2985.6±641.2)ng/mL、AUC0-1:(9682±4478)ng·h/mL;参比制剂的t1,2:(1.96±0.52)h、tmax:(2.90±0.85)h、Cmax:(3231.4±923.5)ng/mL、AUC0-1:(9388±4125)ng·h/mL。以AUC0-1计算,与参比制剂相比受试制剂中泮托拉唑的相对生物利用度为(104.9±26.1)%。结论泮托拉唑钠肠溶片试验制剂与参比制剂在健康人体内具有生物等效性。

关 键 词:泮托拉唑  生物利用度  生物等效性  高效液相色谱法

Pharmacokinetics and relative bioavailability and bioequialence of Panto- prazole Sodium Enteric-Coated Tablet in healthy volunteer
SUI Miao,WANG Xiaobo,XI Ronggang,SUN Jiadan. Pharmacokinetics and relative bioavailability and bioequialence of Panto- prazole Sodium Enteric-Coated Tablet in healthy volunteer[J]. China Medical Herald, 2013, 10(9): 9-11,14
Authors:SUI Miao  WANG Xiaobo  XI Ronggang  SUN Jiadan
Affiliation:1.State Agencies Drug Clinical Trials, the 210th Hospital of PLA, Liaoning Province, Dalian 116021, China; 2. Dalian Medical University, Liaoning Province, Dalian 116015, China
Abstract:Objective To evaluate the bioavailability and bioequivalence of two formulation of Pantoprazole Enter- Coated Tablet in healthy volunteers. Methods Single oral dose of two Pantoprazole Sodium Enteric-Coated Tablets were given to 20 healthy volunteers in a randomized 2-way cross-over study. The blood samples were collected at 0 h, and 0.75, 1.0, 1.5, 2.0, 2.5, 3.0,3.5, 4.0, 5.0, 6.0, 8.0, 10.0, 12.0 h after taking 40 mg of Pantoprazole Sodium Enter- ic-Coated Tablet test preparation and preparation, and with repeated sampling of the crossover drug administration 7 d after clearance. The concentrate toprazole in plasma Pantoprazole was determined by HPLC. The pharmaeokinetie pa- rameters were calculated and compared statistically to evaluate the relative bioequivalenee between the two prepara- tions of pantoparazole sodium by WinNonlin 5.2.1 software. Results The major pharmaeokinetic parameters of two Pantoprazole Sodium Enteric-Coated Tablets test preparation and reference preparation were as follows, t1/2: (1.83± 0.56) h, tmax: (2.80±0.62) h, Cmax: (2985.6±641.2) ng/mL, A UC0-1: (9682±4478) ng h/mL, t1/2: (1.96±0.52) h, tmax: (2.90± 0.85) h, Cmax: (3231.4±923.5) ng/mL, A UC0-1: (9388±4125) ng-h/mL, respectively. The relative bioavailability of test preparation was (104.9±26.1)%. Conclusion Statistical analysis showes Pantoprazole Sodium Enteric-Coated Tablets test preparation and reference preparation are bioequivalent in Chinese healthy volunteers.
Keywords:Pantoprazole  Bioavailability  Bioequivalence  HPLC
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号